Reports

Ideas That Generate Results

European Erythropoietin Market Outlook 2022

European Erythropoietin Market Outlook 2022

Format :  Adobe Reader (PDF) Upto 24 hour delivery
Publish Date : Oct, 2016| No. of Pages : 90

Share |
 
Please make your selection :
Electronic Access - Single User License
US$ 1500.00
CD-ROM Mail Delivery
US$ 1700.00
Hard Copy Mail Delivery
US$ 1700.00
Electronic Access - Multi-User License
US$ 2500.00
1. Analyst View

2. Research Methodology

3. European Protein Therapeutics Market
     3.1 Protein Therapeutics Market Vs Pharmaceutical Market
     3.2 Current and Future Market Analysis for 2022
     3.3 Market Segmentation

4. Erythropoietin Market - Introduction

5. European Erythropoietin Market Outlook 2022
     5.1 By Segment
            5.1.1 Biologics
            5.1.2 Biosimilar

6. European Erythropoietin Market by Country Outlook 2022
     6.1 France
            6.1.1 Market Size
            6.1.2 By Segment
            6.1.3 By Type
            6.1.4 By Application
     6.2 Italy
            6.2.1 Market Size
            6.2.2 By Segment
            6.2.3 By Type
            6.2.4 By Application
     6.3 Germany
            6.3.1 Market Size
            6.3.2 By Segment
            6.3.3 By Type
            6.3.4 By Application
     6.4 Spain
            6.4.1 Market Size
            6.4.2 By Segment
            6.4.3 By Type
            6.4.4 By Application
     6.5 UK
            6.5.1 Market Size
            6.5.2 By Segment
            6.5.3 By Type
            6.5.4 By Application

7. Patents and R&D Pipeline Analysis

8. Market Dynamics
     8.1 Drivers
            8.1.1 Rising Focus on Developing Biosimilars in the Region
            8.1.2 Use of Innovative Technologies for EPO Development
            8.1.3 Rising Number of Elderly People
            8.1.4 Growth in Chronic Diseases Incidences
            8.1.5 Growing Pressure to Reduce Healthcare Expenditure in the Region
     8.2 Challenges
            8.2.1 Expensive Biologics
            8.2.2 Side-Effects of EPO
            8.2.3 Threat of Subsitute for CKD Anemia

9. Key Players Analysis
     9.1 Amgen Inc.
            9.1.1 Business Overview
            9.1.2 Product Portfolio
            9.1.3 Financial Overview
     9.2 Johnson & Johnson
            9.2.1 Business Overview
            9.2.2 Product Portfolio
            9.2.3 Financial Overview
     9.3 Roche Group
            9.3.1 Business Overview
            9.3.2 Products Portfolio
            9.3.3 Financial Overview
     9.4 Pfizer Inc.
            9.4.1 Business Overview
            9.4.2 Product Portfolio
            9.4.3 Financial Overview
     9.5 Novartis
            9.5.1 Business Overview
            9.5.2 Product Portfolio
            9.5.3 Financial Overvie
     9.6 Teva Pharmaceuticals Ltd.
            9.6.1 Business Overview
            9.6.2 Products Portfolio
            9.6.3 Financial Overview
     9.7 Stada Arzneimittel AG
            9.7.1 Business Overview
            9.7.2 Products Portfolio
            9.7.3 Financial Overview
     9.8 Sanofi
            9.8.1 Business Overview
            9.8.2 Products Portfolio
            9.8.3 Financial Overview
     9.9 3SBio Inc.
            9.9.1 Business Overview
            9.9.2 Products Portfolio
     9.10 Dr. Reddy's Laboratories
              9.10.1 Business Overview
              9.10.2 Products Portfolio
              9.10.3 Financial Overview
Not able to find data you are looking for? Ask our Research Analyst.

media citation

get in touch

Please fill-in the information below.